They have SCLC that has progressed or relapsed after at least two previous lines of therapy, including at least one platinum-based treatment They have a tumor tissue sample available They do not have unresolved side effects from previous treatments They have epNEC or LCNEC of the lung that progressed or relapsed, after at least one platinum-based treatment The cancer has spread to the brain and is growing uncontrollably They received a previous anti-cancer treatment that targets DLL3 They have interstitial lung disease, which refers to a group of diseases that causes inflammation and scarring of the lungs They have a weak immune system that struggles to fight off diseases. Also referred to as immunodeficient What is the percentage of patients whose tumors shrunk by at least 30% This is referred to as the ORR How long patients remain on treatment before the treatment stops working or the cancer progresses? This are referred to as DOR and PFS What are the side effects related to the treatment? These are referred to as TRAEs How long do patients live after the start of treatment? This is referred to as OS How often do the side effects occur? What are the effects of the treatment on the patients’ quality of life? Disclosures This study was funded by Boehringer Ingelheim. This summary is based on a poster presentation at AACR-NCI-EORTC 2023, Boston, MA, USA, October 11–15, 2023. The authors were fully responsible for all content and editorial decisions of the associated infographic Congress presentation authors Valentina Gambardella, Alastair Greystoke, Martin Reck, Meiruo Liu, Martha Mueller, Ulrich Duenzinger, Emily B Bergsland, Taofeek Owonikoko Disclaimer: BI 764532 is an investigational agent and has not been approved by any regulatory authority Reference 1. Wermke M, et al. J Clin Oncol 2023;41(suppl 16):abstr 8502 Acknowledgments The authors thank the patients and their caregivers for making the study possible. Medical writing support for the development of this infographic summary was provided by Frans Everson (PhD) of Ashfield MedComms, an Inizio Company, and funded by Boehringer Ingelheim Abbreviations CD3, cluster of differentiation 3; DLL3, delta-like 3; DOR, duration of objective response; IgG, immunoglobulin G; ORR, objective response rate; OS, overall survival; PFS, progression- free survival; TRAEs, treatment related adverse events What is the study design? Where is the trial taking place? What is BI 764532 and why is it important? How does BI 764532 work? The DareonTM-5 study will test how safe and effective BI 764532 is in patients with SCLC, epNEC, or LCNEC of the lung at two dose levels that were selected during Phase I CD3 is present on immune cells called T-cells that are key to initiating immune responses. DLL3 is present on the surface of many SCLC, epNEC, and LCNEC of the lung tumors BI 764532 acts as a bridge between tumor cells and T-cells. When it binds to T-cells they become activated. Activated T cells release toxins and cytokines - substances that attract other immune cells - leading to tumor cell death DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T-cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas Who can take part in the study? What are the key questions that the trial will answer? Inactive T-cell CD3 DLL3 Cancer cell Human IgG- like structure BI 764532 anti-DLL3 anti-CD3 Given the promising activity of BI 764532 in patients with DLL3-positive SCLC, epNEC, and LCNEC of the lung (NCT04429087), researchers have designed a Phase II clinical trial called DareonTM-5 (NCT05882058). BI 764532 is an IgG-like ‘T-cell engager’ investigational compound. It binds to immune system cells and to cancer cells that express DLL3 Many tumors can grow unchecked by evading the immune system DLL3 is a protein found on the surface of some cancer cells but not on healthy cells Cancers that express DLL3 and could be targeted with BI 764532